- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | UKHSA unveils high-risk pathogen list to drive innovation | ||
| 12:46 | Trump tariffs drive pharma manufacturing to US but risk inflation and disruption | ||
| 11:46 | EMA to review GSK's Nucala for COPD treatment expansion | ||
| 11:46 | Sermonix and Regor to enhance breast cancer treatment options | ||
| Mo | Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry | ||
| Mo | Tempero secures $70m to advance addiction treatment candidate | ||
| Mo | Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge | ||
| Mo | Rising Sirturo resistance highlights urgent need for new TB therapies | ||
| Mo | Alberta partners Siemens and the Alberta Cancer Foundation | ||
| Mo | Augustine secures $85m to advance Charcot-Marie-Tooth candidate | ||
| Mo | FDA approves IND application for Everest's cancer vaccine | ||
| Mo | AstraZeneca to invest $2.5bn in R&D centre in China | ||
| Fr | China conditionally approves Hutchmed's Tazverik for follicular lymphoma | ||
| Fr | European agencies catch up with speedier regulatory pathways for CGTs in the US | ||
| Fr | Global funding cuts reversing decades of tuberculosis progress, WHO says | ||
| Fr | How to manage regulatory complexities with clinical trial data | ||
| Fr | Menarini to enhance BPDCN detection with VisualDx's link | ||
| Fr | FDA approves Johnson & Johnson's Tremfya to treat Crohn's disease | ||
| Do | Servier and Black Diamond sign deal for solid tumours therapy | ||
| Do | International Reference Pricing (IRP) 2024: A year in review | ||
| Do | Roche's discontinued Alzheimer's drug shows signs of preventing onset | ||
| Do | Pfizer sells 7.3% stake in Haleon for $3.3bn | ||
| Do | Oxford BioTherapeutics and Roche link on antibody cancer treatments | ||
| Do | Blood cancers dominate CAR-T pipeline | ||
| Mi | USPTO allows patents for Remedy's large hemispheric infarction drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
